Welcome to our dedicated page for Veracyte SEC filings (Ticker: VCYT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Interpreting Veracyte’s SEC disclosures can feel like decoding a genomic sequence: reimbursements, CLIA lab costs, and RNA-sequencing R&D are buried in dense language. If you have ever searched for “Veracyte SEC filings explained simply� or wondered whether a spike in thyroid test volumes appears in the latest numbers, this page is built for you.
Stock Titan pairs every submission to EDGAR with AI-powered summaries that translate jargon into plain English. Whether you need the Veracyte quarterly earnings report 10-Q filing to confirm margin trends or want Veracyte Form 4 insider transactions real-time to gauge executive confidence, our platform delivers insights as soon as the document hits the wire.
- 10-K: Get the Veracyte annual report 10-K simplified—see how test-volume growth offsets R&D spend without reading 200 pages.
- 10-Q: Instantly surface segment revenue in our Veracyte earnings report filing analysis.
- 8-K: Follow laboratory accreditation news with Veracyte 8-K material events explained.
- Form 4: Track Veracyte executive stock transactions Form 4 and complete Veracyte insider trading Form 4 transactions in one click.
- DEF 14A: Review Veracyte proxy statement executive compensation without sifting through legal prose.
Our expert analysis connects each filing to what drives value for a genomic diagnostics company—test adoption, payer coverage and intellectual property. Use the dashboard to set alerts, compare quarters, and export data; you’ll be understanding Veracyte SEC documents with AI instead of scanning line-by-line.
Veracyte Director Karin Eastham received a grant of 9,321 restricted stock units (RSUs) on June 18, 2025, as reported in this Form 4 filing. The RSUs were awarded at $0 cost and will vest in full on either:
- The first anniversary of the grant date (June 18, 2026), or
- Immediately prior to Veracyte's next annual stockholder meeting, whichever comes first
- Additionally, full vesting occurs upon any change in control of the company
Following this transaction, Eastham now beneficially owns 23,228 shares of Veracyte common stock directly. This equity grant appears to be part of the company's director compensation program. The filing was signed by Jonathan Wygant as attorney-in-fact on June 23, 2025.
Veracyte Director Evan Jones received a grant of 9,321 restricted stock units (RSUs) on June 18, 2025. Following this transaction, Jones beneficially owns a total of 43,664 shares directly.
Key terms of the RSU grant:
- RSUs vest in full on the first anniversary of the grant date
- Alternative vesting occurs immediately prior to the company's next annual stockholder meeting, if earlier
- Accelerated vesting provision triggers upon a change in control
- Grant price: $0
The Form 4 was filed on June 23, 2025, within the required reporting window. The transaction was executed under transaction code 'A' indicating an acquisition of securities. This equity grant appears to be part of the company's director compensation program.
Veracyte Director Robert S. Epstein received a grant of 9,321 restricted stock units (RSUs) on June 18, 2025. Following this transaction, Epstein's direct ownership increased to 73,919 shares.
Key terms of the RSU award:
- Vesting occurs in full on the first anniversary of the grant date
- Alternative vesting trigger: immediately prior to the company's next annual meeting of stockholders, if earlier
- Accelerated vesting provision in the event of a change in control
- Grant price: $0
The Form 4 was filed on June 23, 2025, within the required reporting window. The transaction was executed under transaction code 'A' indicating an acquisition of securities. This equity grant appears to be part of Veracyte's director compensation program.
Form 4 filing for Veracyte, Inc. (VCYT) discloses that director Eliav Barr received 9,321 restricted stock units (RSUs) on 18-Jun-2025. The grant price is shown as $0 because RSUs are awarded, not purchased. After the award, Barr’s direct ownership rises to 51,189 common shares.
The RSUs vest 100 % on the first anniversary of the grant or immediately before the next annual shareholder meeting, whichever occurs first. Full vesting also accelerates upon a change-in-control event. No derivative transactions were reported, and no sales occurred.
This filing signals routine board compensation rather than an open-market purchase. While it incrementally increases insider alignment with shareholders, the share count is small and has minimal dilution impact for Veracyte’s ~72 million outstanding shares (figure not in filing). Investors typically view RSU awards as neutral to slightly positive, given the absence of cash outlay and the long-term incentive structure.
Veracyte, Inc. (VCYT) – Form 4 Insider Filing
Director Thomas F. Miller reported the award of 9,321 restricted stock units (RSUs) on 18 June 2025. The RSUs were granted at no cost as part of routine director compensation and will vest in full on the first anniversary of the grant date or immediately before the company’s next annual shareholders’ meeting, whichever occurs first. Vesting also accelerates upon a change in control. Following the grant, Miller’s direct beneficial ownership increased to 25,828 common shares. No open-market purchases, sales, or derivative transactions were disclosed. The filing represents a standard equity compensation event and results in only immaterial dilution relative to Veracyte’s total shares outstanding.
FAQ
What is the current stock price of Veracyte (VCYT)?
What is the market cap of Veracyte (VCYT)?
